Unveiling Solventum (SOLV) Q3 Outlook: Wall Street Estimates for Key Metrics

Core Insights - Wall Street analysts expect Solventum (SOLV) to report quarterly earnings of $1.43 per share, reflecting a year-over-year decline of 12.8% with revenues projected at $2.09 billion, a slight increase of 0.3% from the previous year [1] Earnings Projections - Revisions to earnings projections are crucial for predicting investor behavior, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock performance [2] Key Metrics Estimates - Analysts estimate 'Net Sales- MedSurg' at $1.20 billion, indicating a year-over-year increase of 1.9% [4] - 'Net Sales- Purification and Filtration' is projected to be $213.86 million, reflecting a decline of 10.1% from the previous year [4] - 'Net Sales- Health Information Systems' is expected to reach $337.47 million, showing a year-over-year increase of 3.5% [4] - 'Net Sales- Dental Solutions' is forecasted at $318.05 million, indicating a 1.6% increase from the prior year [5] Operating Income Estimates - 'Operating Income- MedSurg' is expected to be $207.50 million, down from $243.00 million reported in the same quarter last year [5] - 'Operating Income- Purification and Filtration' is estimated at $29.51 million, compared to $20.00 million from the previous year [6] - 'Operating Income- Health Information Systems' is projected to reach $106.94 million, slightly up from $105.00 million reported last year [6] - 'Operating Income- Dental Solutions' is expected to be $71.27 million, down from $72.00 million in the prior year [7] Stock Performance - Solventum shares have returned -5% over the past month, contrasting with the Zacks S&P 500 composite's +1% change, with a Zacks Rank 2 (Buy) indicating expectations of outperforming the market in the near future [7]